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bOral Pathology, Faculty of Dentistry, Tanta University, EgyptAbstractBackground: The aim of our study was to evaluate the effect of local application of melatonin gel on the healing of surgically
induced periodontal osseous defects in diabetes-induced rabbits.
Material and methods: Diabetes induction was done for 28 rabbits, then, acute periodontal osseous defects were done. Rabbits
were divided into: group I: periodontal defects filled with collaplug saturated with placebo gel and group II: periodontal defects
filled with collaplug saturated with 2 mg melatonin gel. The expression of RANKL m RNA in the gingival biopsies was examined
by real time RT-PCR. Histological and histomorphometric evaluation were performed for both groups at 3 and 6 weeks.
Results: The levels of RANKL mRNA expression were significantly increased at 2 weeks after diabetes induction. Then, ten days
after application of melatonin gel, the level of expression of RANKL significantly decreased as compared to control group.
Histologically and histomorphometrically, there was a high significant increase in the percentage of new bone formation and the
number of osteoblasts in melatonin-treated group as compared to control group. The number of osteoclasts significantly decreased
in melatonin-treated group in both examination periods.
Conclusion: The local application of 2 mg melatonin gel offers a promising therapeutic approach for an efficient bone and PDL
regeneration.
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Periodontal diseases are multifactorial infections
elicited by a complex of bacterial species that interact
with host tissues and cells causing the release of a
broad array of inflammatory cytokines, chemokines
and mediators, some of which lead to destruction of the
periodontal structures. [1,2].the Faculty of Dentistry, Tanta University.
8.003
1 (Rightest GM300, BIONIME corporation, Switzerland).
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disease are currently considered to fall under the um-
brella of ‘‘osteoimmunology’’ [3]. This increased
recognition of the complex interactions between the
immune system and bone led to the development of the
interdisciplinary osteoimmunology field, which seeks
to translate an understanding of the mechanisms gov-
erning the interface between the skeletal and immune
systems into therapeutic strategies for the treatment of
disorders characterized by bone loss [4e7].
The first component identified for a novel pathway
regulating bone resorption and remodeling is osteo-
protegerin (OPG), which was discovered in mice via
genomics-based approach [8]. Due to its bone-
protective effects, it was named osteoprotegerin, or
osteoclasts inhibitor factor (OCIF) [9,10]. OPG, a
soluble protein that is one of the TNF receptors
(TNFRs), has contrasting properties to the Receptor
activator of nuclear factor-kappa B ligand (RANKL)
mediated biological effects because it acts as an in-
hibitor that suppresses RANKL interaction, leading to
a decrease in osteoclastogenesis [8,11].
RANKL, a membrane-bound or soluble protein
belonging to the TNF superfamily, is primarily pro-
duced in osteoblastic lineages and activated T cells,
stromal cells and fibroblasts. [12e14] It exerts its
biological effects through binding to its receptor, the
receptor activator of NF-kB (RANK) on osteoclasts
[15]. it is also expressed in cells of the monocyte/
macrophage lineage, including osteoclastic precursors,
B and T cells, dendritic cells and fibroblasts [16].
A large evidence base is available to describe the
mechanisms of the pathobiology of the interactions
between diabetes and periodontitis. Many of which are
strikingly similar to those associated with the classic
diabetic complications, including retinopathy, ne-
phropathy, neuropathy, macrovascular diseases, and
altered wound healing. Evidence suggested that dia-
betes mellitus may modulate periodontal tissue
destruction by reducing the polymorphonuclear
leukocyte functions including chemotaxis, adherence
and phagocytosis [18,19].
It was shown that diabetes up-regulates the pro-
duction of inflammatory cytokines and chemokines
[20], leading to increased inflammation, tissue damage,
and apoptosis in patients who have periodontitis
[21e23].
Pharmacological agents have been investigated to
prevent the detrimental effects of diabetes on wound
healing, among them, aminoguanidine that appears to
prevent systemic complications of diabetes through
preventing the formation of collagen cross-linkagesproduced by the formation of advanced glycation
endproducts (AGEs). [24e28]
In addition, it was found that, melatonin is an indol-
amine produced in various parts of the body, mainly in
the pineal gland. [30] This gland producesmelatonin in a
circadian manner, synchronizing a number of biologic
processes in a 24-h, dayenight rhythm [31]. It acts as
antioxidant, a free-radical scavenger [32,33] and an
immunomodulatory agent [34,35].
Inflammatory processes, such as periodontitis, may
trigger an increase in plasma melatonin concentrations,
this leads to an increase in salivary melatonin where
the indoleamine may exert a protective role by
improving the organism’s defensive response to the
periodontal inflammatory process due to its antioxidant
and anti-inflammatory effects [36e39].
Cutando et al [40] correlated the degree of peri-
odontal disease and IL-2 levels with melatonin con-
centrations in the plasma and saliva of diabetic
patients. It was reported that plasma and salivary
melatonin concentrations showed a bi-phasic response
in the diabetic patients.
Accordingly, the present study was conducted in
order to clarify the potential of local application
melatonin gel on the enhancement of wound healing in
experimentally induced periodontal osseous defects in
diabetes-induced rabbits.
2. Materials & methods
Twenty eight rabbits about 2:2.5 kg in weight were
selected and housed in the Faculty of Pharmacy, Phar-
macology Department, Tanta University. All animals
were injected intra-peritoneally with a single dose of
streptozotocin 65 mg/kg solution (dissolved in 50 mM
citrate buffer, pH 4.5). After two weeks, blood glucose
level monitored from marginal ear vein using gluc-
ometer.1 Animals with blood glucose levels greater than
300 mg/dl were enrolled in the surgical phase [42].
Periodontal defect preparations were performed on
the distal aspect of the lower right mandibular central
incisor for all the selected rabbits. All surgical pro-
cedures were performed under general anesthesia
(Ketamine I.M., 44 mg/kg and xylazine I.M., 5 mg/kg
[43]. Disinfection of the surgical site was done by
betadine mouth wash, and local anesthesia (mepacine).
An angular bone defect measuring >5 mm from a
reference notch was created on the root surface at the
level of the distal crest of the alveolar bone till another
one on the root surface at the bottom of the defect,
Table 1
Summarizing the mean values and standard deviation of real time RT-
PCR for mRNA of RANKL expression in group I and group II in the
study evaluation periods and the inter-groups comparison.
RANKL
mRNA
expression
Group (I)
Placebo
treated
Group (II)
Melatonin
treated
T-test. P value
Baseline (non-
diabetic)
Healthy
Mean  SD
0.175  0.105
Mean  SD
0.161  0.095
0.361 0.721 ns
T-test 5.325 6.332
P1 0.001*** 0.011*
At 2 weeks after
diabetes
induction
Mean  SD
0.985  0.526
Mean  SD
1.451  1.207
0.325 0.197 ns
T-test 0.536 7.523
P2 0.519 ns 0.001***
At ten days after
treatment
Mean  SD
0.962  0.496
Mean  SD
0.193  0.115
5.645 0.001***
T-test 5.302 0.417
P3 0.001*** 0.429 ns
* significant.
*** highly significant.
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mounted on a low speed straight hand piece [44].
Animals were randomly divided into 2 equal groups:
Group _: The control group, represented by fourteen
diabetic rabbits, were treated with a collagen sponge2
(Colla-plug) about 5 mm  5 mm saturated with pla-
cebo gel (methyl cellulose) inserted into the defect.
Group II: The melatonin-treated group, represented
by another fourteen diabetic rabbits, were treated with
a collagen sponge (Colla-plug) about 5 mm  5 mm
saturated with 2 mg of melatonin gel3 and inserted into
the defect.
2.1. Post-operative care
The animals were fed a soft diet (green leaf)
throughout the evaluation period to reduce the chance
of mechanical interference with healing during food
intake. Topical 0.12% chlorhexidine (CHX) (betadine
mouth wash) solution was applied once daily.
2.2. Gingival biopsies for RANKL assessment
Gingival biopsies were obtained from all the ani-
mals (group I & group II) before induction of diabetes,
during the surgical procedure and after ten days from
surgical procedure for RANKL assessment by quanti-
tative polymerase chain reaction (RT-PCR).2 (Calcitek, Inc. Plainsboro, NJ. O b 853).
3 (Amoun pharmaceuticals, Ltd).2.2.1. RNA extraction
Gingival biopsies were obtained, rinsed with cold
sterile saline solution, and stored in a sterile Eppendorf
containing RNA-later4 at 70 C for checking the
mRNA level of RANKL. Total RNA from the gingival
biopsies was extracted using MagNA Pure LC Total
Nucleic Acid Isolation Kit5 according to the manu-
facturer’s recommendation.
2.3. Histological evaluation
Fourteen rabbits (7 from each group) were sacri-
ficed after 3 weeks and the remaining 14 rabbits (7
from each group) were sacrificed after 6 weeks. Tissue
specimens which consisted of bone segment of the
mandible contained central incisors were stained with
hematoxylin and eosin (H&E) stain. Other deparaffi-
nised sections were stained with Masson trichrome.
2.4. Histomorphometric analysis
Bone histomorphometry was performed on IBM
compatible computer using free software Image J, a
Java application which runs in most operative systems,
for all rabbits. The software calculated the area of
newly formed bone in relation to the total bone area
found in the digitalized histopathological photos.
* The percentage of new bone formation was calcu-
lated through AN/At  100.
 (AN) New bone formation area which will be
calculated in square micrometre.
 (At) Total bone area in square micrometres [45].
3. Results
3.1. RANKL assessment results (Table 1)
Data analysis of group I (placebo-treated) demon-
strated that the mean mRNA levels of RANKL expres-
sion was (0.175  0.105) at the baseline (healthy
animals). After diabetes induction, the mean levels of
RANKL expression increased up to (0.985 0.526)with
a statistical significant difference where (P1 < 0.05).
Then, 10 days after placebo gel treatment, the mean
levels slightly decreased with a negligible amount to
(0.962  0.496) this difference was statistically insig-
nificant compared to 2 weeks post diabetes induction
mean value (0.985  0.526) (P2 > 0.05). However, the4 (Ambion Inc., Austin, TX, USA).
5 (ROSHE eUSA).
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treatment recorded a significant increase compared to the
mean baseline value (0.175  0.105) (P3 < 0.05).
Regarding group II (melatonin-treated) showed that,
the mean baseline mRNA levels of RANKL expression
was (0.161  0.095). Two weeks after diabetes in-
duction, the mean levels of RANKL expression obvi-
ously increased to (1.451  1.207) which was
statistically significant compared to the mean baseline
value (P1 < 0.05). However, 10 days after melatonin
gel treatment, the mean levels of RANKL expression
significantly decreased to (0.193  0.115) approxi-
mating nearly to the mean base line value
(0.161  0.095) (P2 < 0.05). There was a non-
significant difference between the mean baseline
value of RANKL expression (0.161  0.095) and the
mean values of RANKL expression after 10 days of
melatonin treatment (1.451  1.207) (P3 > 0.05).
T-paired student test was used to compare the mean
levels of gene expression of RANKL between group (I)
and group (II) at different studied evaluation periods. It
was observed that there were no statistically significant
differences between (both group I and group II) at
baseline and at 2 weeks after diabetes induction eval-
uation periods (P > 0.05). While a high significant
difference was observed between both groups at ten
days after treatment evaluation period (P < 0.05),
where the melatonin treated group (group II) showed a
marked lower mean levels of mRNA RANKL expres-
sion (0.193  0.115) compared to the mean levels of
group I (0.962 þ 0.496).
3.2. Histological results
3.2.1. H & E stained sections
At three weeks: Group I (placebo-treated): About
six cases exhibited signs of inflammation, long apical
epithelial proliferation extended toward the reference
point B, infiltration of periodontal ligaments with in-
flammatory cells, and poor healing of dentine and
cementum related to reference notches also observed.
Only one case exhibited focal area of osteoid tissue
formation. However, in group II (the melatonin-
treated): Five out seven cases showing an excellent
healing of the osseous defect that exhibits normal
periodontal ligament, focal area of osteoid tissue, area
of actually new bone formation, and completely healed
reference notch B with dentin and cementum.
At six weeks: Group I: All cases showed multiple
collections of osteoclasts, irregular bone margin, thick
dilated blood capillaries and chronic inflammatory cell
infiltration. However, in group II: Six out of sevencases showed complete osseous healing with healthy
periodontal ligament and new bone formation.Histological view of the placebo-treated group after
3 weeks showing long apical epithelial proliferation
EYY, partially degenerated PL Y fibers reaching the
reference point (B) at the base of defect. (H&E stained
section X200).Histological view for placebo-treated group at 6
weeks displaying irregular bone margin, collection of
multiple osteoclasts (OST.C) and thick walled dilated
bL cap. (H&E X200).
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treated group after 3 weeks, showing a nearly healthy
periodontal ligament (PL), dilated blood, capillaries
(bl. Cap) presented at the base of the defect. (H&E
stained section X200).H&E stained section of the melatonin-treated group
at 6 weeks exhibiting an apparent thin layer of new
bone formation, in addition to the presence of fibro-
vascular PL. fibers. (H&E 200).
3.2.2. Masson trichrome stained sections
At three weeks: Group I: Five cases out of 7 showed
disoriented less amount of newly formed collagen
multiple areas of degeneration. In addition to the
presence of osteoclasts in all cases. While, Group II:
Six out of seven cases showed thick well oriented
newly formed collagen fibers, areas of osteoid tissue,
and focal area of newly formed bone with smooth
regular margin.
At (6) weeks: Group I: all cases showed multiple
collections of osteoclasts, irregular bone margin and
fine disoriented collagen fibers. However, in group II:
All cases showing well oriented thick collagen fiber
and thick area of new bone.Masson trichrome stained section of group I after 3
weeks displaying irregular bone margin and large area
of degenerated periodontal ligament P.L.Masson trichrome stained section of group I after 6
weeks displaying multiple collection of osteoclasts
(OST.C), irregular bone margin and fine disoriented
collagen fibers (colla.f).Masson trichrome stained section of group II after 3
weeks displaying fibro-vascular P.L, area of osteoid
tissues (ost.b) (Masson X 200).
Graph 2. Comparison between the numbers of osteoclasts at 3 weeks
and 6 weeks intervals.
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weeks displaying well oriented thick collagen fiber
(colla. F) and thick area of new bone (N.B).
3.3. Histomorphometrical results
3.3.1. Percentage of new bone formation
Group (I): It was demonstrated that the mean per-
centage of new bone formation was (2.51  1.11%) at
3 weeks. While, at 6 weeks, this percentage increased
to be (9.42  1.05%), recording a high statistical sig-
nificant difference where (P < 0.05).
Group II: The mean of new bone formation showed
high percentage histomorphometrically at 3 weeks,
(8.70  0.99%). This percentage continued to increase
to reach (12.55 þ 1.08%) at 6 weeks. These data
showed high statistically significant difference of both
evaluation periods (3 vs 6 weeks) (P < 0.05).
Collectively a high significant difference was
recorded comparing both groups at both evaluating
periods, recording a significant increase in the per-
centage of new bone formation in group II vs group I.
Gph (1)
3.3.2. The number of bone cells osteoclasts &
osteoblasts
Concerning Osteoclasts at group I, the mean num-
ber obtained from 10 fields per case, was (3.28  1.11)
cells at 3 weeks, which decreased slightly to be
(2.57  0.78) at 6 weeks with no statistical significant
difference (P > 0.05).
However at group II, the mean number of osteo-
clasts was (1.14  0.69) cells at 3 weeks, which started
to increase slightly to be (1.57 þ 0.78) cells after 6
weeks, showing no statistical difference (P > 0.05).
Using t-test, at 3 and 6 weeks evaluation periods for
both groups a high significant decrease in the mean
number of osteoclasts was recorded for group II vs
group I, (P < 0.05). Gph (2)Graph 1. Comparison between the percentages of new bone forma-
tion for group I & group II at 3 weeks and 6 weeks intervals.Regarding Osteoblasts at group I, the mean number
in ten fields per case was (7.42  1.90) cells at 3
weeks. This mean value increased to be (9.14  167)
cells at 6 weeks. There was no statistically significant
differences recorded comparing both evaluation pe-
riods (P > 0.05).
Also at group II, the mean number was
(21.57  6.62) cells at 3 weeks, which increased to be
(23.28 þ 9.19) cells at 6 weeks. This difference was
not statistically significant (P > 0.05).
Using t-test, to compare both tested groups at 3 and
6 weeks evaluation periods showed that, there was a
high significant increase in the mean number of oste-
oblasts in group II vs group I, where was
[(7.42  1.90) vs (21.57  6.62)] at 3 weeks and
[(9.14  167) vs (23.28 þ 9.19)] at 6 weeks for group I
and group II respectively (P < 0.05). Gph (3)
4. Discussion
Melatonin has many positive aspects, it is an
endogen, it is non-toxic when administered in local or
systemic forms [48]. It acts as an antioxidant and free
radical scavenger, as an immunomodulatory agent and
as a promoter of bone formation [49e52].
In the present study, significantly increased levels of
RANKL expression in diabetes-induced rabbits at 2Graph 3. Comparison between the means number of osteoblasts at 3
weeks and 6 weeks intervals.
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(healthy animals) were recorded. Several cellular and
molecular mechanisms could be proposed to explain
the up-regulation of RANKL expression observed with
diabetes. One of these involves the non-enzymatic
glycation of proteins and consequent production and
accumulation of advanced glycation end products
(AGEs) in tissues [53]. The interaction between AGEs
and its receptor (RAGE), which present in different
types of cells, enhanced the expression of pro-
inflammatory cytokines including IL-1, 17 and TNF-
a. These pro-inflammatory cytokines increased
RANKL expression by various cells [54,55].
In addition, chronic hyperglycemia may modulate
bone metabolism by direct effects of the AGE-RAGE
interplay on bone cells, which in turn induce
RANKL expression [56]. Also, increased RANKL
expression may be explained by increased T-cell acti-
vation and proliferation during diabetes [57,58].
Moreover, by histological examination, we noticed
that, there was a heavy infiltration of the periodontal
ligament by chronic inflammatory cells and also long
junctional epithelium in the placebo-treated (group I)
which may explain the elevation in RANKL expression
with diabetes, as epithelial and inflammatory cells are
considered to be a source of RANKL [59].
These results were supported by Ref. [57] who
studied RANKL-mediated alveolar bone loss in dia-
betic mice by using flow cytometry. Their results
showed that diabetic mice exhibited higher alveolar
bone loss compared with pre-diabetic and non-diabetic
mice when infected by the gram-negative anaerobes
that is associated with higher T-cell proliferation which
expressed higher percentage of membrane-bound
RANKL.
Additionally our results were consistent with
Durate et al [46], who investigated the levels of
mRNA expression of multiple pro-inflammatory cyto-
kines including RANKL from gingival biopsies of
healthy and diabetic human gingival tissues by using
real time RT-PCR for measuring RANKL expression.
They demonstrated that, mRNA levels for pro-
inflammatory cytokines including IL-1b, IL-6, IL-8,
and RANKL were significantly higher in the diabetes
group than in the healthy control group.
Furthermore, In 2010 Santos [60] and his col-
leagues studied the level of RANKL/OPG ratio in
gingival crevicular fluid (GCF) of controlled and
poorly controlled diabetes in periodontally involved
patients using ELISA, they found that this ratio was
higher in poorly controlled than well controlled dia-
betes. They concluded that poorly controlled individualmay have a greater risk of tooth supporting bone loss.
The authors claimed that, their work was the first study
to show possible modulation of RANKL/OPG ratio in
sites with periodontitis according to glycemic status of
subjects with type 2 diabetes mellitus.
In the current study, it was noted that the levels of
RANKL expression decreased significantly after
application of melatonin. This observation may be
relevant to molecular mechanisms of melatonin which
acts on cells of osteoblastic origin, including bone
marrow stromal cells through melatonin receptors on
these cells (considered a source of RANKL), resulting
in suppression of RANKL expression [12,61].
Another molecular mechanism mediated by mela-
tonin is that it reportedly binds to active sites of COX2,
which indicated that it acts as a natural inhibitor of the
function of this enzyme. As, COX2 gives prostaglandin
(PGE2) which induces bone resorption indirectly by
stimulating osteoblasts to produce RANKL, so inhi-
bition of COX-2 with this indolamine will result in
decrease in RANKL production [62,63].
Masson trichorme stained sections showed a thick
well oriented newly formed collagen fibers in both
evaluation periods (3 & 6 weeks) in melatonin-treated
group, as compared to the placebo-treated group which
showed disoriented less amount of collagen fibers. This
may be explained by the influence of melatonin on
fibroblasts activity and the stimulatory effect of mela-
tonin on the synthesis of type I collagen fibers [64].
Interestingly, from (H & E) stained section, the
melatonin-treated group showed an excellent healing
that exhibit normal periodontal ligament without
invading inflammatory cells, this is in contrast to the
placebo-treated group which exhibit signs of inflam-
mation represent with heavy infiltration of periodontal
ligament with chronic inflammatory cells in both
evaluation periods (3 & 6 weeks). This may be
attributed to the well-known potent antioxidant and
anti-inflammatory properties of melatonin [65].
Additionally, melatonin-treated group showed
complete healing represented by focal areas of osteoid
tissues with areas of new bone formation at 3 weeks,
then it progressed in calcification to show complete
osseous healing at 6 weeks. These observations were
confirmed by the histomorphometric analysis, as it was
recorded that, the number of osteoclasts decreased
significantly with melatonin application compared to
placebo application at 3 weeks and in 6 weeks for
(group I& group II) respectively.
This might be explained by the action of melatonin
on OPG and RANKL molecules. It was demonstrated
that, melatonin application in vitro up-regulated the
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of RANKL in mouse osteoblast line cells MC3T3-E1
cells [66]. Consequently, inhibition of osteoclasts
maturation, differentiation, activation and increased
apoptosis occurred [67e69].
Also, several in-vivo studies on this indolamine
concluded that, The antioxidant properties of melatonin
might justify its therapeutic use in diseases in which
free-radical damage is a major aspect of the condition
like infectious and inflammatory disorders [51,70].
The current finding agreed with the study of
Koyama et al., [66], who performed an in-vivo and in-
vitro study to document their findings. Regarding the
in vivo section, they demonstrated that daily intra-
peritoneal injection with melatonin for 4 weeks
significantly reduced bone resorption parameters and
osteoclasts number. In the in-vitro section, they found
that application of melatonin in a dose dependent
manner for precursors of osteoclasts inhibited the
resorption pits formation and the activity of osteoclasts
beside a decrease in RANKL expression.
The histomorphometric findings of the present study
have also demonstrated the distinguished role and in-
fluence of melatonin in terms of the significant
increased number of osteoblasts that was much more
superior relative to control cases (group I) receiving
placebo treatment at all-time points as shown by their
mean values.
These results may be attributed to the stimulatory
effects of melatonin on the proliferation and differen-
tiation of osteoblasts [71,72] . It also could be
explained by the direct action of melatonin on the
osteoblasts cells as it induces a higher rate of maturity
of pre-osteoblasts to osteoblasts, both in quantity and
velocity, with a higher rate of production of the
osseous matrix and its corresponding calcification [73].
Moreover, it is worthy-noted that, 50 nM melatonin
promotes development of bone sialoprotein, and other
bone proteins markers, including alkaline phosphatase,
osteopontine, osteocalcine, it also reduces the period of
differentiation of pre-osteoblast line cells into matured
osteoblasts from 21 days (which is normal) to 12 days
[71,72].
In the current study, regarding the new bone forma-
tion, a significant percentage (9% and 13%) with mela-
tonin treatment was obtained in both evaluation periods
(3 and 6 weeks) respectively versus (3% and 9%)
with placebo treatment at the same evaluation periods.
The obvious significant amount of newly formed
bone could be supported and explained by a significant
decrease in osteoclasts number as well as significant
increase in osteoblasts number recorded currently.Also, it may be explained by the ability of mela-
tonin to stimulate certain genes which control the
presence of determined proteins at the osteoid matrix.
Accordingly, it has been shown that melatonin is
capable, after a period of 5 and 9 days, of stimulating
the development of osteocalcin, sialoprotein, and
alkaline phosphatase [72].
5. Conclusion
The results of the present study showed a strong
correlation between the real time RT-PCR findings with
histological and histomorphometric evaluations. Our
findings strongly suggested that, the use of melatonin in
periodontal bony defects is promising in a way to
promote the acceleration of bone healing and increasing
new bone formation. Besides, it could be speculated
that treatment with melatonin during diabetes may exert
a protective role for all organs and in particular the oral
cavity. From our point of view, the functional aspects of
melatonin needs additional investigations and may
prove to be a fertile area of research.
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